Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings
| Autor: | Nazanene H. Esfandiari, Charles Burant, Angela Subauste, Christos S. Mantzoros, Nevin Ajluni, Adam H. Neidert, Baris Akinci, Rasimcan Meral, Jeffrey W. Innis, Rita Hench, Thomas L. Chenevert, Akin Eraslan, Amit R. Rupani, Hero K. Hussain, Diana Rus, Hari S. Conjeevaram, Elif A. Oral, Marwan K. Tayeh, Barbara J. McKenna |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Leptin
Male medicine.medical_specialty Leptin Deficiency Lipodystrophy medicine.diagnostic_test business.industry Partial Lipodystrophy General Medicine medicine.disease Gastroenterology Article Metreleptin chemistry.chemical_compound Insulin resistance chemistry Non-alcoholic Fatty Liver Disease Liver biopsy Internal medicine medicine Humans Steatosis business |
| Zdroj: | Med (N Y) |
| ISSN: | 2666-6340 |
| Popis: | BACKGROUND. Recombinant leptin therapy reverses nonalcoholic steatohepatitis (NASH) in leptin-deficient lipodystrophy. We inquired if leptin therapy would improve nonalcoholic steatohepatitis in more common forms of this heterogeneous condition. METHODS. Nine male patients with relative leptin deficiency (level < 25th percentile of body mass index- and gender-matched United States population) and biopsy-proven NASH and 23 patients with partial lipodystrophy and NASH were recruited for two distinctive open-label trials. Participants received leptin therapy in the form of metreleptin for 12 months. The primary endpoints were the global nonalcoholic steatohepatitis scores from paired liver biopsies scored blindly. FINDINGS. Of 9 participants recruited in the relative leptin deficiency treatment study, 7 completed 12-months of therapy. Mean global NASH scores were reduced from 8 ± 3 to 5 ± 2 (range: from 1 to 6, P = 0.004). In the partial lipodystrophy study, 19 of 22 subjects completed 12 months of treatment, and 18 completed a second liver biopsy. Global NASH scores also reduced significantly from 6 ± 2 to 5 ± 2 (range: from −2 to 4, P = 0.008). In both studies, the predominant changes were in steatosis and hepatic injury scores. CONCLUSION. Our findings show that patients with NASH associated with both relative leptin deficiency and partial lipodystrophy have reductions in hepatic steatosis and injury in response to exogenous leptin therapy. Moreover, leptin deficiency may have regulatory effects in mediating fat deposition and ensuing injury in the liver. TRIAL REGISTRATION. ClinicalTrials.gov NCT00596934 and NCT01679197. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|